Aeglea BioTherapeutics Acquires Spyre Therapeutics
June 22, 2023
Aeglea BioTherapeutics completed a stock-for-stock acquisition of Spyre Therapeutics, a privately held biotechnology company advancing antibody therapeutics for inflammatory bowel disease (IBD). Concurrent with the acquisition Aeglea announced a $210 million PIPE led by Fairmount Funds to advance Spyre’s pipeline (lead programs SPY001 and SPY002) into clinical studies and fund operations into 2026.
- Buyers
- Aeglea BioTherapeutics, Inc.
- Targets
- Spyre Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.